A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

(2009) Emma K. Hansson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

(2009) Anthe S. Zandvliet et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients

(2009) Amelia Ramon-Lopez et al.   PHARMACEUTICAL RESEARCH

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study

(2008) Etienne G. C. Brain et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin

(2008) Anthe S. Zandvliet et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression

(2008) Steven J. Kathman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients

(2008) Jürgen B. Bulitta et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

(2008) J. E. Latz et al.   CLINICAL CANCER RESEARCH